April 08, 2024 11:36 AM Eastern Daylight Time
BUSINESS WIRE
Riassunto: Lo studio clinico comparativo di fase 3 condotto sul candidato biosimilare Prolia ® e Xgeva ® (denosumab) HLX14 soddisfa gli endpoint primari
Tweet
View Full Size
Download
Full Size
JPEG
,
4326
x
1105
,
287.5 KB
Small
JPEG
,
480
x
123
,
17.2 KB
Preview
JPEG
,
144
x
37
,
3.4 KB
Thumbnail
JPEG
,
120
x
31
,
2.5 KB
Smart Multimedia Gallery
View and Share Logo
Download Full Size
Download Small
Share
Facebook
Twitter
LinkedIn
Delicious
Reddit
StumbleUpon
Digg
MySpace
Newsvine
Google Bookmark
Yahoo! Bookmark
Email
All News
|
News with Multimedia
>
Press Release: Riassunto: Lo studio clinico comparativo di fas...